the cxcr4-cxcl12 axis in ewing sarcoma promotion of tumor growth rather than metastatic diseasecxcr4-cxcl12轴在尤因肉瘤促进肿瘤的生长,而非转移性疾病.pdfVIP

下载本文档

2
0
约6.22万字
约 9页
2017-09-12 发布于上海
举报
版权申诉

the cxcr4-cxcl12 axis in ewing sarcoma promotion of tumor growth rather than metastatic diseasecxcr4-cxcl12轴在尤因肉瘤促进肿瘤的生长,而非转移性疾病.pdf

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

the cxcr4-cxcl12 axis in ewing sarcoma promotion of tumor growth rather than metastatic diseasecxcr4-cxcl12轴在尤因肉瘤促进肿瘤的生长,而非转移性疾病

Berghuis et al. Clinical Sarcoma Research 2012, 2:24 /content/2/1/24 CLINICAL SARCOMA RESEARCH RESEARCH Open Access The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease 1,2 2 2 3 4 5 Dagmar Berghuis , Marco W Schilham , Susy J Santos , Suvi Savola , Helen J Knowles , Uta Dirksen , 6 3 1 2* Karl-Ludwig Schaefer , Jukka Vakkila , Pancras CW Hogendoorn and Arjan C Lankester Abstract Background: Chemokine receptor CXCR4, together with its ligand CXCL12, plays critical roles in cancer progression, including growth, metastasis and angiogenesis. Ewing sarcoma is a sarcoma with poor prognosis despite current therapies, particularly for patients with advanced-stage disease. Lungs and bone (marrow), organs of predilection for (primary/metastatic) Ewing sarcoma, represent predominant CXCL12 sources. Methods: To gain insight into the role of the CXCR4-CXCL12 axis in Ewing sarcoma, CXCR4, CXCL12 and hypoxia-inducible factor-1α protein expression was studied in therapy-naïve and metastatic tumors by immunohistochemistry. CXCR4 function was assessed in vitro, by flow cytometry and proliferation/ cell viability assays, in the presence of recombinant CXCL12 and/or CXCR4-antagonist AMD3100 or under hypoxic conditions. Results: Whereas CXCR4 was predominantly expressed by tumor cells, CXCL12 was observed in both tumor and stromal areas. Survival analysis revealed an (expression level-dependent) negative impact of CXCR4 expression (p 0.04). A role for the CXCR4-CXCL12 axis in Ewing sarcoma growth was sugg